Primavera Retinal Implant: 3-Year Vision Gains

The European Primavera trial reports that vision gains from the PRIMA retinal implant are sustained three years after implantation in patients with geographic atrophy from dry age-related macular degeneration (AMD). At the three-year mark, the majority of treated eyes continued to show improved reading ability on a standardized test compared to their baseline, with no delayed safety concerns reported. This article explains the trial’s findings, how the implant works, and what these results mean for people living with severe vision loss.

What the Primavera Trial Measured

The Primavera study is a European clinical trial evaluating the PRIMA implant, a subretinal photovoltaic device designed for patients with geographic atrophy, the advanced form of dry AMD that destroys central vision. The trial’s primary endpoint was the change in best-corrected visual acuity, but the key functional measure was the ability to read letters on a standardized near-vision chart (the ETDRS chart) using a special viewing system built into the implant.

Three-year data presented at major ophthalmology conferences showed that:

• Most treated eyes maintained or improved their reading speed and letter recognition compared to baseline.
• Patients who had the implant activated (with the associated glasses and camera) could read lines of text they could not read without the system.
• No device-related serious adverse events were reported in the long-term follow-up period.

The trial’s results are considered a proof-of-concept that a photovoltaic subretinal implant can provide sustained functional benefit in a condition that currently has few treatment options.

How the PRIMA Implant Works

The PRIMA system consists of three components:

1. The implant: a 2-millimeter-wide, 30-micrometer-thick silicon chip with 378 photodiodes, surgically placed beneath the retina in the area of photoreceptor loss.
2. The glasses: a pair of video glasses with a camera that captures the scene and projects a near-infrared light pattern onto the retina.
3. The pocket processor: a small wearable unit that processes the camera image and controls the light projection.

When the near-infrared light hits the implant’s photodiodes, it generates an electrical current that stimulates the remaining inner retinal neurons (bipolar cells), bypassing the dead photoreceptors. The brain then interprets these signals as visual patterns. Unlike earlier retinal implants, the PRIMA chip does not require a power cable or an intraocular coil; it receives both power and data entirely through the light beam, making surgery less invasive and the device more durable.

Why Three-Year Data Matters

Retinal implants face two major long-term challenges: biological stability (the implant must not cause inflammation, fibrosis, or damage to the remaining retina) and functional persistence (the brain must continue to interpret the artificial signals). Three-year data from the Primavera trial address both:

• Safety: The absence of late-onset complications, such as implant migration, retinal detachment, or chronic inflammation, supports the device’s biocompatibility.
• Efficacy: Sustained improvement in reading tests suggests that the implant does not lose its ability to stimulate the retina over time, and that patients do not become “habituated� to the signal in a way that reduces benefit.

For comparison, the earlier Argus II implant (a different, epiretinal device) showed stable but modest visual function at five years, but its adoption was limited by the need for a trans-scleral cable and a bulky external unit. The PRIMA’s wireless design aims to overcome those drawbacks.

Who Is Eligible for the Implant?

The Primavera trial enrolled adults with geographic atrophy due to dry AMD, with:

• Best-corrected visual acuity between 20/200 and 20/500 in the study eye (legal blindness in many jurisdictions).
• No active neovascular (wet) AMD in the study eye.
• No other retinal disease that would prevent implant function (e.g., severe glaucoma, optic neuropathy).
• Ability to undergo vitrectomy surgery and to use the external glasses and processor.

Importantly, the implant does not restore normal vision; it provides a low-resolution, black-and-white view that allows reading large letters, recognizing shapes, and moving independently. Patients must undergo extensive training to learn to interpret the pixelated images.

Common Misconceptions and Limitations

One common misconception is that the PRIMA implant “cures� dry AMD. It does not. It is a visual aid, not a therapy that halts or reverses the underlying disease. The implant does not prevent further progression of geographic atrophy; it only stimulates the remaining retinal neurons. Another misconception is that the implant works immediately after surgery. In reality, patients need several months of rehabilitation to learn to use the device effectively, and the visual field is limited to the area covered by the chip (about 10 degrees of visual angle).

Limitations of the current system include:

• Reading is only possible with the external glasses and processor; without them, the implant is inactive.
• The field of view is narrow, so patients must move their head to scan text.
• The implant is not suitable for patients with no remaining inner retinal function, such as those with end-stage glaucoma or retinitis pigmentosa with severe retinal remodeling.

Costs and Availability

As of this writing, the PRIMA implant is not yet commercially available. It has received the CE mark in Europe, which allows it to be sold in the European Economic Area, but it is not yet approved by the U.S. Food and Drug Administration. The company behind the device, Pixium Vision, has stated that it is seeking a commercial partner to bring the product to market. The cost of the implant and surgery is not publicly disclosed, but based on comparable retinal implants (e.g., Argus II, which was priced around $150,000 in the U.S.), it is likely to be expensive. Insurance coverage is uncertain and will depend on regulatory approvals and reimbursement decisions in each country.

Alternatives and Future Directions

For patients with geographic atrophy, there are few treatment options. The only approved therapies for dry AMD are the complement inhibitors (e.g., pegcetacoplan and avacincaptad pegol), which slow the growth of atrophy but do not restore vision. Low-vision aids, such as magnifiers, telescopic glasses, and electronic reading devices, remain the standard of care. Gene therapies targeting the retinal pigment epithelium are in clinical trials, but they aim to prevent further degeneration, not to replace lost photoreceptors.

Other retinal implant approaches include:

• Argus II (epiretinal, discontinued but still used in some patients).
• Alpha-AMS (subretinal, from Retina Implant AG, but the company ceased operations in 2020).
• Optogenetic therapies (e.g., using light-sensitive proteins to make remaining retinal cells respond to light, currently in early trials).

The PRIMA implant’s advantage lies in its wireless design and its specific targeting of dry AMD, which is the most common cause of untreatable blindness in older adults.

Frequently Asked Questions

Does the Primavera trial prove that the implant works for all patients with dry AMD?

No. The trial involved a small cohort (around 30 patients), and results are reported as group averages. Some patients showed greater improvement than others, and a few did not improve at all. The implant is not a guaranteed fix; it is a high-tech visual aid that requires patient selection and training.

Can the implant be removed if it fails?

Yes, the implant can be surgically removed, but removal is not routine and carries risks of retinal damage. In the Primavera trial, no explantations were reported at three years, suggesting good short-term tolerance.

Will the implant work for people with wet AMD or other retinal diseases?

The PRIMA implant is specifically designed for dry AMD with geographic atrophy. It is not intended for wet AMD, which is treated with anti-VEGF injections, nor for conditions like retinitis pigmentosa that affect the inner retina. The implant requires a reasonably intact inner retinal layer to function.

How does the implant compare to using a magnifier or a CCTV reader?

Magnifiers and CCTV readers are cheaper, non-invasive, and can provide higher magnification. However, they require the user to move the text under the lens, which is tiring. The PRIMA implant provides a head-mounted display that allows hands-free reading, but the resolution is much lower than a camera-based system. For many patients, a simple magnifier is still more practical.

Is the three-year data the final word on long-term safety?

No. Three years is a meaningful milestone, but the implant is expected to remain in the eye for a decade or more. Longer-term follow-up is needed to assess the risk of late complications such as fibrosis, device corrosion, or retinal detachment. The company is continuing to monitor trial patients.

Related

• CSV Demo to Production AI Agent: Systems You Must Add
• AI Lethal Decisions: How to Tell if a System Decides Life or Death
• Lego Display Frames vs Shelves: Which Is Right?